Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Elkhalifa Marwa, Orbai Ana-Maria, Magder Laurence S, Petri Michelle, Alarcón Graciela S, Gordon Caroline, Merrill Joan, Fortin Paul R, Bruce Ian N, Isenberg David, Wallace Daniel, Nived Ola, Ramsey-Goldman Rosalind, Bae Sang-Cheol, Hanly John G, Sanchez-Guerrero Jorge, Clarke Ann E, Aranow Cynthia, Manzi Susan, Urowitz Murray, Gladman Dafna D, Kalunian Ken, Werth Victoria P, Zoma Asad, Bernatsky Sasha, Khamashta Munther, Jacobsen SØren, Buyon Jill P, Dooley Mary Anne, Vollenhoven Ronald van, Ginzler Ellen, Stoll Thomas, Peschken Christine, Jorizzo Joseph L, Callen Jeffery P, Lim Sam, Inanc Murat, Kamen Diane L, Rahman Anisur, Steinsson Kristjan, Franks Andrew G
Аннотация
METHODS: The dataset consisted of 1384 patients, 657 with a consensus physician diagnosis of SLE and 727 controls with other rheumatic diseases. Anti-beta 2 glycoprotein I isotypes were measured by ELISA. Patients with a consensus diagnosis of SLE were compared to controls with respect to presence of anti-beta 2 glycoprotein I. Among patients with SLE, we assessed the association between anti-beta 2 glycoprotein I IgA and clinical manifestations.
RESULTS: The prevalence of anti-beta 2 glycoprotein I IgA was 14% in SLE patients and 7% in rheumatic disease controls (odds ratio, OR 2.3, 95% CI: 1.6, 3.3). It was more common in SLE patients who were younger patients and of African descent (p = 0.019). Eleven percent of SLE patients had anti-beta 2 glycoprotein I IgA alone (no anti-beta 2 glycoprotein I IgG or IgM). There was a significant association between anti-beta 2 glycoprotein I IgA and anti-dsDNA (p = 0.001) and the other antiphospholipid antibodies (p = 0.0004). There was no significant correlation of anti-beta 2 glycoprotein I IgA with any of the other ACR or SLICC clinical criteria for SLE. Those with anti-beta 2 glycoprotein I IgA tended to have a history of thrombosis (12% vs 6%, p = 0.071), but the difference was not statistically significant.
CONCLUSION: We found the anti-beta 2 glycoprotein I IgA isotype to be more common in patients with SLE and in particular, with African descent. It could occur alone without other isotypes.